Skip to main content
Smart Investors Daily
OK

NASDAQ · OKUR

OnKure Therapeutics, Inc.

Healthcare · Biotechnology

$2.63

Up+$0.12 (+4.56%)

Updated Nov 17, 2026, 1:28 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
44.44M
P/E ratio
-6.67
Dividend yield
0.00%
52-week range
$2.01 – $5.38
Volume
891.35K
Avg. volume
131.89K

Price performance · OKUR

OKUR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

OKUR closed at $2.63 after 20 trading sessions, up 16.89% for the selected period.

Last close
$2.63
Period change
+16.89%
Period low
$2.25
Period high
$3.39
Daily close
View OHLC price history
OKUR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$3.03$3.0796$2.60$2.63891.35K
Nov 12, 2026$3.33$3.33$2.925$3.01286.83K
Nov 11, 2026$3.40$3.59$3.345$3.36205.83K
Nov 10, 2026$3.15$3.42$2.99$3.385281.89K
Nov 9, 2026$2.88$3.21$2.76$3.19814.19K
Nov 6, 2026$2.47$2.88$2.31$2.865555.82K
Nov 5, 2026$2.54$2.58$2.315$2.525325.17K
Nov 4, 2026$2.53$2.65$2.51$2.59876.95K
Nov 3, 2026$2.60$2.60$2.44$2.50219.38K
Nov 2, 2026$2.64$2.72$2.47$2.59500.84K
Oct 30, 2026$2.61$2.67$2.53$2.62306.76K
Oct 29, 2026$2.63$2.68$2.44$2.62427.59K
Oct 28, 2026$2.56$2.661$2.46$2.63282.59K
Oct 27, 2026$2.49$2.72$2.475$2.595320.24K
Oct 26, 2026$2.59$2.625$2.38$2.475258.09K
Oct 23, 2026$2.62$2.62$2.48$2.52240.86K
Oct 22, 2026$2.30$2.59$2.28$2.58243.94K
Oct 21, 2026$2.37$2.40$2.25$2.30232.76K
Oct 20, 2026$2.25$2.475$2.25$2.36235.15K
Oct 19, 2026$2.10$2.26$2.02$2.25501.47K

Latest OKUR news

The latest Smart Investors Daily articles mentioning OKUR.

OKUR research

Overview

Company profile and research snapshot.

Company profile

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$35.00
Implied upside
—
Analysts
—
OKUR recent ratings
DateFirmRatingTarget
Aug 14, 2026OppenheimerOutperform—
Jul 20, 2026HC Wainwright & Co.Buy—
Mar 16, 2026HC Wainwright & Co.Buy—
Aug 26, 2025HC Wainwright & Co.Buy—
Mar 18, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

OnKure Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

-- Announces PANORAMA, an OnKure-sponsored, large-scale, multiregional registry designed to characterize the natural disease course and treatment patterns of people living with vascular anomalies -- Executing IND-enabling activities for next-generation PI3Kα pan-mutant-selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027 BOULDER, Colo., Nov. 04, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage

Benzinga · Nov 4, 2026

OnKure Therapeutics Q3 EPS $(0.36) Misses $(0.34) Estimate

OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 66.97 percent increase over losses of $(1.09) per share

Yahoo · Aug 31, 2026

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026. The OnKure management team will host one-on-one meetings during the conference. Interested investors should contact their Morgan

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.